text:
Members of our Scientific Advisory Committee are respected leaders in research and on treating women with ovarian cancer.
Beth Y. Karlan, MD, Chair
Vice Chair, Women's Health Research
Professor, Department of Obstetrics and Gynecology
Director, Cancer Population Genetics
Jonsson Comprehensive Cancer Center
Beth Y. Karlan, M.D. is Professor and Vice Chair of Women's Health Research in the Department of Obstetrics and Gynecology at the David Geffen School of Medicine, University of California Los Angeles (UCLA). She is also Director of Cancer Population Genetics at the Jonsson Comprehensive Cancer Center at UCLA. Dr. Karlan's research focuses on ovarian and other women's cancers as well as inherited cancer susceptibility. She has authored over 300 research publications and is an American Cancer Society Clinical Research Professor. She is the Editor-in-Chief of the scientific journals Gynecologic Oncology and Gynecologic Oncology Reports. In 2012, Dr. Karlan was appointed by the White House to serve on the National Cancer Advisory Board and in 2015 she was elected to membership in the National Academy of Medicine. In 2018 Dr. Karlan was named a Fellow of the American Society of Clinical Oncology.
Ronald D. Alvarez, MD, MBA
Professor and Chairman, Department of Obstetrics and Gynecology
Betty and Lonnie Burnett Endowed Chair of Obstetrics and Gynecology
Ronald D. Alvarez, MD, MBA, is Professor and Chairman of the Department of Obstetrics and Gynecology and holds the Betty and Lonnie S. Burnett Endowed Chair of Obstetrics and Gynecology at Vanderbilt University Medical Center in Nashville, Tennessee.
Dr. Alvarez received his B.S. degree in 1979 from Louisiana State University in Baton Rouge, Louisiana, and his M.D. in 1983 from Louisiana State University School of Medicine in New Orleans, Louisiana. He completed his residency in Obstetrics and Gynecology in 1987 and his fellowship in Gynecologic Oncology in 1990, both at the University of Alabama at Birmingham (UAB) in Birmingham, Alabama. He received his M.B.A. in 2013 from Auburn University in Auburn, Alabama.
Dr. Alvarez was previously, Professor and Ellen Gregg Shook Culverhouse Chair in the UAB Division of Gynecologic Oncology, for which he served as Director from 2003-2014, and Vice-Chair of the UAB Department of Obstetrics and Gynecology. His long-term research interests have included the development of novel therapeutics for ovarian cancer and new screening and prevention strategies for cervical cancer. He has been the recipient of several NCI and other industry funded grants in support of his research in gene therapeutics for ovarian cancer, including projects funded by the UAB Ovarian Cancer SPORE. He was a co-principal investigator in the cervical neoplasm vaccine projects included in the Johns Hopkins/UAB Cervical SPORE. He was principal investigator for the UAB NCTN LAPS. He is currently co-chair of the NRG Oncology Gynecologic Cancer Committee.
Dr. Alvarez has served on study sections for the NCI Clinical Oncology Section and the Department of Defense's Ovarian Cancer Research Program. Dr. Alvarez has published over 250 articles in various peer-reviewed journals and has served on the editorial board of Gynecologic Oncology. In 2013, he served as President of the Society of Gynecologic Oncology and he currently serves as Director of Gynecologic Oncology Division for the American Board of Obstetrics and Gynecology.
Deborah K. Armstrong, MD
Associate Professor, Oncology
Associate Professor, Obstetrics and Gynecology
Johns Hopkins School of Medicine
Dr. Armstrong is Associate Professor of Oncology and Associate Professor of Obstetrics and Gynecology at the Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins School of Medicine, as well as an active staff member in the hospital's Oncology Department. She is currently on the editorial review board and peer review panels of publications such as Gynecologic Oncology and Journal of the National Cancer Institute.
Dr. Armstrong also holds positions on committees with the American Society of Clinical Oncology and the Gynecologic Oncology Group. Her research interests in ovarian cancer lie in the genetic aspects of the disease as well as interperitoneal (IP) therapy, biological therapy, and immunologic means of treatment.
Her contributions to the field of ovarian cancer include leading the IP therapy effort, developing new therapeutic cancer treatments, and directing a genetic counseling service at Johns Hopkins to identify and help at risk patients.
Robert C. Bast Jr., MD
Vice President for Translational Research
MD Anderson Cancer Center
Dr. Bast is Vice President for Translational Research at the UT M.D. Anderson Cancer Center. His office facilitates translation of new strategies, drugs and devices from laboratory to the clinic, as well as the movement of human material and data from the clinic to laboratory. Dr. Bast received his B.A. cum laude from Wesleyan University and his M.D. magna cum laude from Harvard Medical School. After completing a medical internship at the Johns Hopkins Hospital, he served as a research associate at the National Cancer Institute. Returning to Boston, Dr. Bast completed a medical residency at the Peter Bent Brigham Hospital and a fellowship in Medical Oncology at the Dana-Farber Cancer Institute. He joined the faculty at Harvard as an Assistant Professor and was subsequently appointed Associate Professor at the Dana-Farber Cancer Institute. Dr. Bast was recruited to the Duke University Medical Center in 1984 as Professor of Medicine, Microbiology and Immunology to Co-Direct the Division of Hematology-Oncology and to serve as Clinical Director of the Cancer Center. In 1987, he became the Director of the Duke Comprehensive Cancer Center and in 1992 he was named Wellcome Clinical Professor of Medicine in Honor of R. Wayne Rundles. In July 1994, Dr. Bast was recruited to head the Division of Medicine at UT M. D. Anderson Cancer Center and to fill the Harry Carothers Wiess Chair for Cancer Research. In 2000, Dr. Bast was appointed Vice President for Translational Research. In 2004, he became the Harry Carothers Wiess Distinguished University Professor for Cancer Research.
Dr. Bast is best known for developing the OC125 monoclonal antibody that led to the production of the CA125 radioimmunoassay. Serum CA125 levels have provided the first generally useful marker for monitoring the course of patients with epithelial ovarian cancer. CA 125 is currently being evaluated as one component of a screening strategy for ovarian cancer. His early studies focused on the use of immunostimulants and monoclonal antibodies for cancer therapy. Over the last 15 years his group has pioneered in defining molecular alterations in ovarian and breast cancers that might serve as targets for therapy as well as diagnosis. His most recent studies have focused on the identification of ARHI, a novel ras-related imprinted tumor suppressor gene that induces autophagy and tumor dormancy. He has led the U.T. M.D. Anderson SPORE in Ovarian Cancer since 1999. Overall, Dr. Bast has published more than 500 articles and chapters, and has edited the textbook Cancer Medicine. He has been recognized by Institute for Scientific Informal as one of the most frequently cited scientists in his field. In 2006 he was recognized with the Smith-Klein Beacham Clinical Laboratories Award, the ISOBM-Abbott Award and an Award for Excellence in Gynecologic Oncology by the International Society of Gynecologic Oncology. He continues to care for patients with breast and ovarian cancer and has been listed in the Best Doctors of America and in America's Top Physicians.
Andrew Berchuck, MD
Co-Director, Duke Comprehensive Cancer Center, Breast/Ovarian Cancer Program
Andrew Berchuck, M.D. attended medical school and received his Obstetrics and Gynecology residency training at Case Western Reserve University in Cleveland, Ohio. His research and clinical training in Gynecologic Oncology was completed at UT Southwestern in Dallas, Texas and Memorial Sloan-Kettering Cancer Center in New York City. For the past 20 years he has been on the faculty at Duke University Medical Center. In addition to caring for women with gynecologic cancers, Dr. Berchuck has been an active scientific investigator. He has published over 200 scientific papers, mostly in the area of ovarian and endometrial cancer genetics. He is Co-Director of the Duke Comprehensive Cancer Center Breast/Ovarian Cancer Program.
Dr. Berchuck has received many national honors including awards for best oral presentation and poster at the Society of Gynecologic Oncologists annual meeting and the Wayne Rundles Award for Excellence in Cancer Research from the Duke Cancer Center. In 2004 he received an award for best scientific presentation at the International Gynecologic Cancer Society meeting. In 2005 he was awarded the Barbara Thomason Ovarian Cancer Professorship by the American Cancer Society.
Dr Berchuck has been actively involved in national activities in his field and was program chair for the 2001 Annual Meeting of the Society of Gynecologic Oncologists and was elected President of the society in 2007. Dr. Berchuck also has served as Chair of a study section for the Department of Defense Ovarian Cancer Research Program, and in the past chaired OCRF's Scientific Advisory Committee.
"Catching Ovarian Cancer Early May Miss Aggressive Tumors."
US News & World Report, March 24, 2009.
ABC News, March 24, 2009.
Jonathan S. Berek, MD, MMS
Laurie Kraus Lacob Professor
Director, Stanford Women's Cancer Center
Senior Advisor, Stanford Cancer Institute
Jonathan S. Berek MD, MMS is the Laurie Kraus Lacob Professor at the Stanford University School of Medicine and a recent past Fellow in the Stanford Distinguished Careers Institute. He helped establish and is the Director of the Stanford Women's Cancer Center, which is one of the first programs in the nation to combine breast & gynecologic oncology with a women's cancer translational research, genetics and supportive services programs. He serves as Senior Advisor, Stanford Cancer Institute, and served as Chair of the Department of Obstetrics and Gynecology from 2005-2017.
A Stanford faculty member since 2005, he is renowned for his expertise in gynecologic oncology, surgical innovation and technique, and research in ovarian cancer, especially immunology and immunotherapy. His past laboratory research focused on fundamental mechanisms of cancer immunology, elucidating growth regulatory pathways for cytokines and their receptors. His current research focuses on clinical trials of novel therapies and immunotherapies for ovarian cancer and collaborations on new diagnostics, screening techniques, and genetics.
An author and editor, Dr. Berek has published more than 320 peer-reviewed manuscripts in the scientific literature, and an equal number of book chapters and monographs. His books, Berek & Hacker's Gynecologic Oncology, now in it's 6th edition, and Berek & Novak's Gynecology, in it's 16th edition, are leading texts in the field. He serves as Editor-in-Chief for Current Opinion in Obstetrics & Gynecology, and immediate past Editor-in-Chief of ASCO Connection.
Professor Berek has extensive involvement and many leadership roles in national and global cancer activities. He is the Past President of the International Gynecologic Cancer Society, and he is one of two representatives from the USA to the International Federation of Obstetrics and Gynecology (FIGO) Gynecologic Oncology Committee, which is responsible for the staging of gynecologic cancers, and he is the Chair of the FIGO Subcommittee on Cervical Cancer. He serves as a Principal Investigator on the Gynecologic Cancer Intergroup (GCIG), the premiere international consortium of 32 cooperative clinical cancer trials groups. He is the Group Chair of the Cooperative Oncologic Gynecology Investigators (COGI), a member group of the GCIG. He is the Chair of the GCIG Education Committee, a member of the Steering Committee for the Cervical Cancer Research Network (CCRN), a group that develops programs for the treatment and clinical research on cervical cancer in limited resourced countries. On behalf of the American Society of Clinical Oncology (ASCO), he is the senior author of the international resource-stratified guidelines for the management of cervical cancer, which provides direction for basic and limited levels of cancer care for women in developing countries.
Professor Berek received his undergraduate degree in English literature and theatre arts, and a Master of Medical Sciences degree in biomedical sciences from Brown University. After earning his Doctor of Medicine from Johns Hopkins University School of Medicine, he completed an internship and residency at the Harvard Medical School, Brigham & Women's Hospital. Before moving to Stanford, he was on the faculty at the UCLA School of Medicine for over two decades, where he served the Chair of the College of Applied Anatomy, Chief of Staff of the UCLA Medical Center, departmental Executive Vice Chair, and Director of Gynecologic Oncology.
In 2003, Dr. Berek received the highly prestigious Sherman Mellinkoff Award from the David Geffen School of Medicine at UCLA. In 2012, he was presented the John C. Fremont Pathfinder Award, given in recognition of significant contributions to society made by a native Nebraskan. Dr. Berek is the 2019 Honoree of the American Cancer Society for his many accomplishments in women's cancer treatment and research.
Molly Brewer, DVM, MD, MS
Professor and Chair, Obstetrics and Gynecology
University of CT Health Center
Dr. Molly Brewer is Chair of the Department of Obstetrics and Gynecology at the University of CT Health Center. She completed medical school at SUNY Syracuse after being in practice as a veterinarian for 8 years. She did her residency in Obstetrics and Gynecology at Oregon Health Sciences University in Portland Oregon, a Galloway fellowship at Memorial Sloan Kettering Hospital and a Gynecologic Oncology fellowship at MD Anderson Cancer Center. Following Dr. Brewer's fellowship, she stayed on the faculty at MDACC for 4 years and completed an MS in the OJOC Program at the University Of Michigan School Of Public Health in Statistics and Clinical Research Design.
Dr. Brewer was a faculty member at the Arizona Cancer Center where she worked with optical scientists and biomedical engineers to develop optical technology to interrogate the ovary for early cancer. Her other research and clinical interests include prevention of ovarian/breast cancer and evaluation of women at risk for cancer.
Ronald Buckanovich, MD, PhD
Director of the Ovarian Cancer Center of Excellence
Co-Director of the Womens Cancer Research Center
Magee-Womens Research Institute
UPMC Hillman Cancer Center
Ronald Buckanovich graduated from Cornell University in 1990 with a B.S. in Genetics and Biochemistry. He then completed the Medical Scientist Training Program and started his life-long study of ovarian cancer. He received his Ph.D. in 1996 from the Rockefeller University and his M.D. in 1998 from Cornell University. Dr. Buckanovich then went on to complete an Internal Medicine residency and a Hematology-Oncology fellowship at the Hospital of the University of Pennsylvania. During his fellowship he continued his research on ovarian cancer, identifying dozens of novel clinical targets and helped to develop a novel therapeutic to enhance tumor vaccine therapy. Dr. Buckanovich joined the University of Michigan as ascended to the ranks of Associate Professor. There he also served an associate director for the Hematology Oncology Fellowship. In 2017 Dr. Buckanovich was recruited to the Magee Women's Research Institute and UPMC Hillman Cancer Center of the University of Pittsburgh as a Professor of Medicine and serves as the Director of Ovarian Cancer Center of Excellence and Co-Director of the Women's Cancer Research Center. His lab has identified a novel population of cancer stem-like cells (CSCs) which may be responsible for ovarian cancer metastasis, chemotherapy resistance and ultimately disease recurrence. His laboratory also identified and characterized a novel population of cancer associated mesenchymal stem cells (MSCs)—normal cells recruited by the cancer to help the cancer grow. His laboratory is now studying the factors which regulate CSCs and MSCs including regulators of asymmetric division and quiescence. His laboratory work has resulted in the initiation of 4 translational clinical trials for the treatment of ovarian cancer. In addition, his group has identified two novel compounds which are now being developed for first in human clinical trials; one which blocks the ability of cancer cells to metastasize, and a second which selectively kills the cancer stem-like cells to reverse chemotherapy resistance. Based on the knowledge he has gained studying the tumor microenvironment, his group is now also looking at ways to enhance anti-tumor immune therapy by targeting host cells in the tumor.
In addition to his laboratory studies, Dr. Buckanovich has a busy clinical practice, specializing in the treatment of ovarian and uterine cancers. He is currently the principal investigator of two clinical trials at the University of Pittsburgh. He has been an author or co-author of 70 original research articles. In recognition of his work, Dr. Buckanovich received a Clinical Investigator Award from the Damon Runyon Cancer Research Foundation, the National Institutes of Health New Innovator – Directors Award, Society of Gynecologic Oncology Best Basic Science Award, and he has been elected to the American Society of Clinical Investigators.
Robert Coleman, MD
Professor, Deputy Chair and Vice Chair of Clinical Research
Ann Rife Cox Chair in Gynecology
Gynecologic Oncology and Reproductive Medicine
Dr. Coleman received his doctor of medicine degree from Creighton University in Omaha, Nebraska and completed his Obstetrics & Gynecology residency at Northwestern University Medical Center in Chicago, Illinois. He then completed his fellowship at The University of Texas MD Anderson Cancer Center in 1993. Prior to joining the M.D. Anderson faculty, he served as Vice Chairman, Department of Obstetrics and Gynecology at the University of Texas, Southwestern Medical Center in Dallas.
Dr. Coleman's research interests include drug discovery and novel therapeutics for ovarian, uterine, and cervical cancer, clinical trial development and statistical design. He serves as the institution's Gynecologic Oncology Group (GOG) principal investigator (PI), serves on the NRG's (formerly the Gynecologic Oncology Group) Ovarian and Developmental Therapeutics Committees, and is PI or co-PI for several GOG prospective clinical trials. He currently is a co-project leader for the MDACC Ovarian SPORE, the MDACC Uterine SPORE, the Ovarian Cancer Research Fund, and the Marcus Foundation, each of which is sponsoring novel therapeutics trials in gynecologic cancers. He also serves as Physician Champion and PI for a new human therapeutic leveraging nanoparticle delivery of gene silencing non-coding RNA (siRNA). He has developed a mentoring program for junior investigator clinical trialists.
Dr Coleman has authored or coauthored over 400 scientific publications, including over 250 peer-reviewed articles, numerous book chapters, monographs, invited articles and textbooks including, The Handbook of Gynecologic Oncology, Clinical Lymphatic Mapping in Gynecologic Cancers, Prognostic and Predictive Factors in Gynecological Cancers, and Atlas of Gynecologic Oncology. In 2012, Dr Coleman was elected to the position of Secretary Treasurer for the International Gynecologic Cancer Society, and was Program Chair for their 2012 biannual meeting. In 2015, he was elected President for the Society of Gynecologic Oncology. He currently serves on the Gynecologic Oncology Group's Board of Directors.
Alan D. D'Andrea, MD
Director, Susan F. Smith Center for Women's Cancers
Director, Center for DNA Damage and Repair
The Fuller-American Cancer Society Professor
Alan D'Andrea is internationally known for his research in the area of DNA damage and DNA repair. Dr. D'Andrea is currently the Fuller-American Cancer Society Professor of Radiation Oncology at Harvard Medical School and the Director of the Center for DNA Damage and Repair at the Dana-Farber Cancer Institute. A recipient of numerous academic awards, he is a former Stohlman Scholar of the Leukemia and Lymphoma Society, and serves on their Medical and Scientific Advisory Board. He recently served as Chairman of the Career Development Selection Committee of the LLS, and Chairman of the NIH Molecular and Cellular Hematology Study Section. He is a Distinguished Clinical Investigator of the Doris Duke Charitable Trust, and a Fellow of the American Association for the Advancement of Science. He is also the recipient of the 2001 E. Mead Johnson Award, the highest award in Pediatric Research, and the 2012 G.H.A. Clowes Memorial Award from the American Association for Cancer Research. He is also currently the Team Leader of the Stand Up To Cancer-Ovarian Cancer Research Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant. Through his work on DNA Repair Biomarkers, he participates in a wide range of clinical trials, largely focused on ovarian, breast, prostate, and bladder cancers. In 2017, he became the Director of the Susan Smith Center for Women's Cancer at the Dana-Farber Cancer Institute.
Ronny I. Drapkin, MD, PhD
Associate Professor, Obstetrics, Gynecology and Pathology
Director, Ovarian Cancer Research Center
Director, Gynecologic Research
Basser Research Center for BRCA
Ronny Drapkin, M.D., Ph.D. recently joined the Abramson Cancer Center at the University of Pennsylvania as Associate Professor of Obstetrics, Gynecology and Pathology and Director of Penn Medicine's Ovarian Cancer Research Center. He also joined the Leadership Team of the Basser Research Center for BRCA as Director of Gynecological Research. He holds the Franklin Payne Chair in Gynecologic Oncology.
Dr. Drapkin has been awarded research grants from the National Institutes of Health, Department of Defense, and numerous foundations. His research activities focus on understanding the pathogenesis of gynecologic malignancies and integrating genomic findings into novel experimental model systems developed in his laboratory. The ultimate goal of his research is to translate important biological principles discovered in the laboratory into clinically useful diagnostic and therapeutic tools.
Dr. Drapkin has authored or co-authored more than 100 peer-reviewed research papers, review articles, and book chapters. He serves on multiple editorial boards, including Gynecologic Oncology and Clinical Cancer Research. He received a B.A. degree with High Honors in Biochemistry from Brandeis University and his M.D. and Ph.D. degrees from the Rutgers-Princeton joint MD-PhD program. After finishing his residency in Anatomic Pathology at the Brigham and Women's Hospital, Dr. Drapkin completed a postdoctoral research fellowship in cancer biology at the Dana-Farber Cancer Institute. He then joined the faculty of Harvard Medical School and the Dana-Farber Cancer Institute until assuming his current position at UPenn.
Annie Ellis
Annie Ellis is a 12-year survivor of recurrent ovarian cancer and 5-year survivor of breast cancer. Annie serves the ovarian cancer community as the Ovarian Cancer Research Alliance's (OCRA) research advocate, on the CDMRP Ovarian Cancer Research Program (OCRP) Integration Panel, and as a patient advocate on RPCI-UPCI's Ovarian Cancer SPORE.
Annie has provided the patient perspective on ovarian cancer and clinical trials at various meetings and events, including a Congressional Briefing on Ovarian Cancer by the Society for Women's Health Research (SWHR), the 2015 Ovarian Cancer Workshop at the FDA, the 2008 Society of Gynecologic Oncology (SGO) Annual Meeting as part of SHARE's Survivor Presentation and OCRF's 2010 Research Symposium and clinical trials video.
Annie has participated in the American Association for Cancer Research (AACR) Scientist↔Survivor Program (AACR SSP) and the Biennial Cancer Survivorship Research Conference Survivor-Researcher Mentor Program. Annie provides peer support through SHARE's Ovarian Helpline and Columbia Presbyterian's Woman to Woman Program.
Ellen L. Goode, PhD
Professor of Epidemiology
Dr. Ellen L. Goode is a Professor of Epidemiology within the Department of Health Sciences Research at Mayo Clinic in Rochester, Minnesota, USA. Her research program focuses on the genetic and molecular epidemiology of ovarian cancer.
To better understand disease origins, Dr. Goode studies women with and without ovarian cancer who are seen at Mayo Clinic. Study participants respond to a research questionnaire and provide a blood sample, which allows for analysis of inherited and lifestyle factors. Tumors from affected women are also studied in order to further classification of clinically relevant histological, molecular, and immunological subtypes.
To find novel inherited factors in ovarian cancer, Dr. Goode examines variants throughout the genome via large collaborations. The international Ovarian Cancer Association Consortium combines data from more than 60 epidemiologic studies.
To better understand the functional impact of inherited and somatic variation, Dr. Goode examines expression and methylation in relation to genetics in the tumors of Mayo Clinic study participants and with the Ovarian Tumor Tissue Analysis consortium.
To tease out the role of immune factors in ovarian cancer risk and outcome, Dr. Goode focuses on the nuclear factor kappa-B family of transcription factors, regulatory T cells, and tumor-infiltrating lymphocytes in large multidisciplinary efforts.
Dr. Goode has contributed to over 275 peer-reviewed manuscripts and served in leadership roles within several ovarian cancer research consortia, the International Genetic Epidemiology Society, and the American Association for Cancer Research.
Dineo Khabele, MD
Director, Division of Gynecologic Oncology
Professor, Obstetrics and Gynecology
The University of Kansas Health System
Dr. Dineo Khabele is a physician and surgeon who diagnoses and treats women with gynecologic cancers. As a physician scientist, she also conducts clinical and translational research studies funded over the years by federal grants and foundation awards, including the Ovarian Cancer Research Alliance. She has presented her work nationally and internationally and has authored over 40 manuscripts. She is an ad hoc reviewer for the Department of Defense Ovarian Cancer Program and a member of the National Institutes of Health Molecular and Integrative Signal Transduction (MIST) Study Section. She is a co-founder and leader of the Vanderbilt Ovarian Cancer Alliance (VOCAL), whose mission is to advance translational, multi-disciplinary research collaborations to develop personalized approaches to diagnose and treat ovarian cancer and collaborate with ovarian cancer survivors and advocates to raise awareness about ovarian cancer.
As an educator, Dr. Khabele is actively involved in mentoring and training the next generation of physicians and scientists and committed to raising awareness about women's cancers and cancer health disparities. Prior to joining Vanderbilt in 2008, she was the Director of Gynecologic Oncology at Meharry Medical College where she remains an adjunct faculty member. She is a member of several medical societies. She is also involved in policy making for the Tennessee Breast and Cervical Cancer Screening Program and served on the Governor-Appointed Task Force to Eliminate Cervical Cancer in Tennessee. She uses her personal hobby of running to advocate for healthy lifestyles and raise awareness about cancer.
Dr. Khabele is board certified in Obstetrics and Gynecology and Gynecologic Oncology and obtained undergraduate and medical degrees from Columbia College and Columbia College of Physicians and Surgeons of Columbia University in New York. She completed her residency in obstetrics and gynecology at The New York Presbyterian Hospital, Weill-Cornell University Medical Center, followed by a clinical fellowship in gynecologic oncology and post-doctoral research training in cancer biology at Albert Einstein College of Medicine and Montefiore Medical Center. She was a scholar of the Reproductive Scientist Development Program and the Amos Medical Faculty Development Program Scholar/Robert Wood Johnson Foundation.
Ernst Lengyel, MD, PhD
Chair and Professor, Department of Obstetrics and Gynecology
Ernst Lengyel, M.D., Ph.D., a Gynecologic Oncologist, is Chair and a Professor in the Department of Obstetrics and Gynecology at the University of Chicago. He graduated magna cum laude from the University of Munich in 1992 with a doctorate in medicine, followed by a research fellowship at MD Anderson Cancer Center. He completed his residency at the University of Munich and then entered the combined Gynecologic Oncology fellowship program at the University of California/San Francisco (UCSF) and Stanford. In 2004, after one year on the clinical faculty at UCSF, he joined the University of Chicago faculty as a research scientist and clinician. In 2008 he was awarded the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research.
Dr Lengyel directs a translational research laboratory focused on understanding ovarian cancer metastasis and on developing and testing new treatments for ovarian cancer. Specifically, he looks at interactions of ovarian cancer cells with the normal cells surrounding them to understand how the cellular microenvironment affects the growth of cancer cells. The major goal of his laboratory is to translate his research findings into novel therapeutic treatments that will improve the survival of those with this devastating disease. His primary clinical focus is the surgical treatment of patients with ovarian cancer.
For more information on Dr. Lengyel's research and clinical practice at the University of Chicago see:
http://obgyn.bsd.uchicago.edu/FacultyResearch/lengyellab.htm
http://www.uchospitals.edu/physicians/ernst-lengyel.html
Douglas A. Levine, MD
Director, Gynecologic Oncology
Head, Gynecology Research Laboratory
Professor, Division of Gynecologic Oncology
Laura and Isaac Perlmutter Cancer Center
New York University Langone Health
Douglas A. Levine MD is gynecologic oncologist who specializes in the surgical treatment of women with known or suspected ovarian or uterine cancers.
In addition to his clinical practice, Dr. Levine is the current Head of the Gynecology Research Laboratory, where he studies cancer prevention, precision medicine, and rare tumors with unmet needs. He serves as the translational scientist on many national clinical trials determining what genomic alterations are associated with response to targeted therapies. He discovered universal mutations in SMARCA4 that drive small cell carcinoma of the ovary, hypercalcemic type. Dr. Levine has an outstanding level of expertise and leadership in ovarian and endometrial cancer research and a deep commitment to women's health.
Dr. Levine has been very active within the NIH-sponsored Cancer Genome Atlas project (TCGA). He served as co-chair of the ovarian, endometrial, uterine carcinosarcoma, and Pan-GYN disease working groups. He is a member of the Scientific Advisory Committee of the Ovarian Cancer Research Alliance, Clearity Foundation, and Honorable Tina Brozman Foundation. He has authored or co-authored more than 220 peer-reviewed articles and two textbooks. Dr. Levine has received funding from the National Cancer Institute, the Department of Defense, Stand Up 2 Cancer, and the Gynecologic Oncology Group. He has been awarded the American Congress of Obstetricians and Gynecologists Mentor Award, served as co-chair of the American Association for Cancer Research Special Conferences on Ovarian and Endometrial Cancers, received the Foundation for Women's Cancer Excellence in Ovarian Cancer Research Prize, is the Assistant Dean of the Department of Defense Ovarian Cancer Academy, the translational science co-chair of the NRG Oncology Corpus Committee, a member of the NCI Cancer Prevention Steering Committee, and Chair of the NCI Cancer Biomarkers Study Section.
Ursula Matulonis, MD, Grants Oversight Chair
Medical Director, Gynecologic Oncology Susan F. Smith Center for Women's Cancers Dana-Farber Cancer Institute Associate Professor of Medicine, Harvard Medical School
Medical Director, Medical Gynecologic Oncology
Disease Center Leader, Medical Gynecologic Oncology Program
Associate Professor, Medicine
Ursula A. Matulonis, MD, is Chief and Director of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She is the first recipient of the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute. She also co-leads the Ovarian Cancer Program within the Dana-Farber/Harvard Cancer Center. Her research focuses on developing new targeted therapies for gynecologic malignancies, with a specific interest in ovarian cancer and endometrial cancer.
Dr. Matulonis has led several PARP inhibitor, anti-angiogenic agent, immunotherapy, and combination trials for ovarian cancer in the United States and internationally. Dr. Matulonis serves on the Massachusetts Ovarian Cancer Task Force, the NRG ovarian committee, and the Scientific Advisory Board for the Ovarian Cancer Research Alliance and the Clearity Foundation. She received the Dana-Farber Dennis Thompson Compassionate Care Scholar award, the Lee M. Nadler "Extra Mile" Award, the Clearity Foundation award, and the Zakim Award at Dana-Farber for patient advocacy.
After receiving her MD from Albany Medical College, she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at the Dana-Farber Cancer Institute in Boston, MA.
Kenneth Nephew, PhD
Professor of Cellular and Integrative Physiology
Professor of Obstetrics and Gynecology
Assistant Director for Basic Science Research
Indiana University Simon Cancer Center
Dr. Nephew is a Professor of Cellular and Integrative Physiology and Obstetrics and Gynecology at Indiana University. He leads the Ovarian Cancer Research Group at the IU Simon Cancer Center (IUSCC), serves as the Assistant Director for Basic Science Research Bloomington, and is a Program Leader of the Walther Cancer Institute, which is affiliated with IU. He is a Full Member of the Tumor Microenvironment and Metastasis Program and the Breast Cancer Program at IUSCC. Dr. Nephew is the former Director of Graduate Education for the Medical Sciences at IU and is highly active in training and educating graduate and medical students in ovarian cancer research. He is the 2016 Indiana University Graduate School Faculty Mentor Award Winner. Professor Nephew joined Indiana University in 1996. He has dedicated his entire professional career to the study of ovarian cancer. Dr. Nephew's ovarian cancer research has been continuously funded by National Institutes of Health (NIH)/National Cancer Institute (NCI) since 1996. He is the Principal Investigator and co-investigator on numerous grants from National Institutes of Health/National Cancer Institute (NIH/NCI), serves on various editorial boards, scientific advisory committees, and review panels for both the NIH, American Cancer Society (ACS), and Department of Defense Ovarian Cancer Research Program.
Dr. Nephew's ovarian cancer research focuses on disease recurrence, and its resistance to chemotherapy. Dr. Nephew has made important contributions defining the characteristics of ovarian cancer stem cells and proposing new strategies to inhibit them. A new paradigm explaining tumor relapse involves the persistence of cancer stem cells. Dr. Nephew is a leader in the field characterizing these malignant cells in ovarian cancer. His collaborative team defined the first phenotype of ovarian cancer stem cells from patient samples. He has shown that ovarian cancer stem cells are chemotherapy resistant and likely responsible for secondary recurrences. His research to target these causative cells in ovarian tumors may enhance the potential to eradicate ovarian cancer. Toward this goal, his laboratory showed that targeting the epigenome, including aberrant DNA methylation (an "epigenetic hallmark" of most cancers including ovarian cancer) inhibited the outgrowth of ovarian cancer stem cells and delayed tumor recurrence. The project is designed to identify and target "epigenetic vulnerabilities" found in the pool of ovarian cancer stem cells that remains after platinum therapy. We will identify how key pathways are epigenetically maintained and regulated in ovarian cancer stem cells. These "epigenetic vulnerabilities" can then be targeted to switch off paths responsible for ovarian cancer stem cell survival after platinum therapy, eradicate the disease and improve the outcome for recurrent ovarian cancer patients.
Dr. Nephew received his undergraduate and graduate (PhD) degrees in Reproductive Physiology from the Ohio State University. He subsequently obtained postdoctoral training in cancer biology at the University of Kansas School of Medicine and then the University of Cincinnati College of Medicine, where he was supported by ACS and NIH postdoctoral fellowships.
Celeste Leigh Pearce, PhD, MPH
Associate Professor and Associate Chair, Department of Epidemiology
Dr. Pearce is an ovarian cancer epidemiologist who studies lifestyle, personal, environmental and genetic factors which influence disease risk. Her group focuses on the role of endometriosis in ovarian cancer risk as well as shared risk factors between the two diseases. The clear cell and endometrioid histotypes of ovarian cancer are associated with endometriosis and it is possible that these ovarian cancers arise from endometriosis. They have identified a shared genetic component between ovarian cancer and endometriosis. They are also currently exploring whether known protective factors such as oral contraceptive use modify the relationship between ovarian cancer and endometriosis.
Another area of investigation for her group is understanding exogenous hormonal factors with respect to ovarian cancer. Oral contraceptive pills are chemopreventive for ovarian cancer, but the reason is unknown. They are carrying out clinical trials to try to uncover the reason for the protection so that they know whether changes in types of oral contraceptives in current use will impact the protective benefit enjoyed by women using the pill today. Conversely, use of menopausal hormone therapy is associated with increased risk of ovarian cancer. Her team is working to understand the precise nature of the association with respect to the type, timing and duration of use of these hormones. They are also studying whether the risk associated with menopausal hormone therapy is different based on underlying genetic variation.
Ultimately, Dr. Pearce is interested in preventing ovarian cancer. It is clear that the best path for ovarian cancer is preventing the disease from occurring in the first place or detecting it early. They have shown that there is a wide range of lifetime risk of ovarian cancer among women in the general population based on their experiences with respect to ovarian cancer risk and protective factors. They are working on developing improved risk stratification models so that women and their doctors can make informed decisions about the preventive strategies available to them now. In addition, this work will identify women appropriate for screening if an effective modality is discovered.
Dr. Pearce earned her PhD at the University of Southern California and had extensive training in genetics at what is now the Broad Institute of MIT and Harvard. She is currently an Associate Professor in the Department of Epidemiology in the School of Public Health at the University of Michigan. She collaborates with investigators from all over the world and is a founding member of the Ovarian Cancer Association Consortium and the Multidisciplinary Ovarian Cancer Outcomes Group. Consortia broaden the impact we can all have on ovarian cancer and she is proud to be a part of these multidisciplinary efforts!
Kunle Odunsi, MD, PhD
Chair, Gynecologic Oncology
Executive Director, Center for Immunotherapy
Co-Leader, Tumor Immunology and Immunotherapy Research Program
Dr. Adekunle "Kunle" Odunsi is Chair of the Department of Gynecologic Oncology, Executive Director of the Center for Immunotherapy and Co-Leader of the Tumor Immunology and Immunotherapy research program at Roswell Park Cancer Institute. He joined RPCI's staff in 2001 as an Attending Surgeon in the Division of Gynecologic Oncology, Department of Surgical Oncology. After earning his medical degree from the University of Ife, Ile-Ife, Nigeria, in 1984, Dr. Odunsi completed postgraduate training in Obstetrics and Gynecology at the Rosie Maternity and Addenbrookes Hospitals, University of Cambridge, UK. He was admitted to the Royal College of Obstetricians and Gynecologists in 1991.
Dr. Odunsi completed a research fellowship in Molecular Oncology and earned his Ph.D. at the Imperial Cancer Research Fund Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, UK. Subsequently, he completed residency training in Obstetrics & Gynecology at the Yale University School of Medicine, New Haven, CT, and clinical fellowship in Gynecologic Oncology at RPCI. He is a Fellow of the Royal College of Obstetricians and Gynaecologists in the United Kingdom. He is also a Fellow of the American College of Obstetricians and Gynecologists.
Dr. Odunsi is licensed by New York State and certified in Obstetrics & Gynecology by the American Board of Obstetrics and Gynecology. He is also board certified in the sub-specialty of Gynecologic Oncology.
Dr. Odunsi's research interests include the molecular characterization of tumor antigens in ovarian cancer and their application to the development of vaccine therapies for the disease. He has authored or co-authored more than 140 journal publications and book chapters. He is Associate Editor for BMC Cancer. He also is an Ad Hoc Reviewer for the American Journal of Obstetrics and Gynecology, BLOOD, BMC Cancer, Cancer Immunity, Cancer Immunology Immunotherapy, Cancer Letters, Cancer Research, Clinical Cancer Research, Expert Opinion on Biological Therapy, Fertility and Sterility, Future Oncology, Gynecologic Oncology, International Journal of Cancer, Journal of Clinical Pathology, Journal of the Society for Gynecologic Investigation, The Lancet, Mayo Clinic Proceedings, Molecular Cancer Therapeutics, Oncogene, Oncology PLoS ONE and the Proceedings of the National Academy of Sciences, U.S.A.
Sandra Orsulic, PhD
Sandra Orsulic, PhD, is a Professor of Obstetrics and Gynecology at Cedars-Sinai Medical Center and a Professor-in-Residence of Obstetrics and Gynecology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). Prior to joining Cedars-Sinai, Dr. Orsulic was Assistant Molecular Pathologist at the Massachusetts General Hospital in Boston, where she also served as Assistant Professor of Pathology at Harvard Medical School. Her research includes studying the mechanisms by which the microenvironment contributes to cancer initiation and metastatic progression, identifying molecular markers for early cancer detection, and generating suitable pre-clinical models for testing targeted therapies. Dr. Orsulic's research on ovarian cancer has been funded primarily by the National Institutes of Health (NIH), Department of Defense (DoD), American Cancer Society (ACS), and Ovarian Cancer Research Alliance (OCRA). Her studies have been published in peer-reviewed journals such as Nature, Cancer Cell, Proceedings of the National Academy of Sciences, USA and Cancer Research. Dr. Orsulic is a member of the OCRA Scientific Advisory Committee and serves on several editorial boards and NIH review panels.
Daniel J. Powell Jr., PhD
Associate Professor, Department of Pathology and Laboratory Medicine
Perelman School of Medicine, University of Pennsylvania
Dr. Daniel Powell Jr. is an Associate Professor in the Department of Pathology and Laboratory Medicine with a secondary appointment in the Department of Obstetrics and Gynecology in the Perelman School of Medicine at the University of Pennsylvania. Dr. Powell is also a member of the Abramson Cancer Center and Penn's Ovarian Cancer Research Center (OCRC) within the Center for Research on Reproduction & Women's Health.
Dr. Powell is a cancer immunologist, well-recognized for his detailed investigations of the immunobiology of cancer, patient T cell responses in the control of their cancer, and the use of translational immunotherapy for effective cancer treatment. His research team is pioneering innovative immunotherapeutic strategies, including tumor-infiltrating lymphocyte-based therapeutics, genetically-modified T cell therapy, dendritic cell-based cancer vaccination and antibody-based immune checkpoint inhibition for the treatment of gynecologic and other cancers. These approaches empower a patient's own immune cells to seek out and destroy their cancer.
Dr. Powell has served as the Deputy Director of PENN's Cell and Vaccine Production Facility (CVPF) within the Abramson Cancer Center and the Director of the Clinical Tumor Tissue Facility (CTTF), in support of multiple Phase I and II immunotherapy trials. He is the IND sponsor for the clinical application of T cell-based cancer immunotherapy, and has aided in the clinical application of adoptive lymphocyte immunotherapy, immunomodulation and cancer vaccination in various cancer types.
Prior to his recruitment to Penn, he and his colleagues developed novel combinatorial approaches for tumor vaccination, investigated the role of immunosuppressive regulatory T cells in cancer, and successfully applied adoptive T cell immunotherapy for the treatment of metastatic melanoma at the Surgery Branch at the National Cancer Institute, NIH.
Dr. Powell serves on various grant review committees, including those for the NIH and NHLBI's PACT, scientific advisory boards for industry, as well as academic committees within the University. His research excellence has been recognized by multiple awards including the American Society of Gene & Cell Therapy's Outstanding New Investigator Award, and multiple NIH Exceptional performance Awards.
Stephen C. Rubin, MD
Chief, Gynecologic Cancer
Paul Grotzinger and Wilbur Raab Chair in Surgical Oncology
Fox Chase Cancer Center
Stephen C. Rubin, M.D., joined Fox Chase Cancer Center at the Chief of Gynecologic Cancer and the Paul Grotzinger and Wilbur Raab Chair in Surgical Oncology in 2014. Prior to joining Fox Chase, he spent 10 years at the University of Pennsylvania Medical Center Professor of Obstetrics and Gynecology and Chief of the Division of Gynecologic Oncology. Dr. Rubin is a nationally recognized expert in the treatment of gynecologic cancers, and he has a special interest in the multidisciplinary management of ovarian malignancies. He has authored more than 250 publications on gynecologic cancer, and has published six textbooks on gynecologic cancers, including Ovarian Cancer (Lippincott), Cervical Cancer and Preinvasive Neoplasia, (Lippincott), the SGO Handbook: Chemotherapy of Gynecologic Malignancies (Lippincott), and Uterine Cancer (Marcel-Deker). Dr. Rubin has been a member of the Ovarian Cancer Committee and the Tumor Biology Committee of the Gynecologic Oncology Group (GOG), and a member of the Council of the Society of Gynecologic Oncologists. He has been a member of the editorial boards of several journals, including Gynecologic Oncology and the Annals of Surgical Oncology, and has also served on the editorial board of OncoLink. He is currently Deputy Editor of Gynecologic Oncology. He previously served for six years as a member of the American Board of Obstetrics and Gynecology's Division of Gynecologic Oncology, and recently returned as Chief of the Division, which is responsible for the fellowship accreditation process and the board certification process in gynecologic oncology nationally. He also serves as a Director of the American Board of Obstetrics and Gynecology, and is an examiner for the oral examinations in both gynecologic oncology and obstetrics and gynecology.
Dr. Rubin is a graduate of the University of Pennsylvania School of Medicine, and did his residency and fellowship at Penn.
Carolyn D. Runowicz, MD
Executive Associate Dean for Academic Affairs
Dr. Runowicz is a graduate of the Thomas Jefferson Medical College in Philadelphia. She did her training in obstetrics and gynecology and completed a fellowship in gynecologic oncology at Mount Sinai School of Medicine and Medical Center in New York City. She was also a Galloway Fellow at the Memorial Sloan Kettering Cancer Center in New York City.
Dr. Runowicz is a nationally prominent expert in gynecologic cancers and women's health. Before coming to FIU, Runowicz was professor of Obstetrics and Gynecology and held the Northeast Utilities Chair in Experimental Oncology at the University of Connecticut School of Medicine. She also served as director of the Carole and Ray Neag Comprehensive Cancer Program at the University of Connecticut Health Center.
Among her many leadership positions in national organizations, she was president of the American Cancer Society, the first woman president of the Society of Gynecologic Oncologists and chair of the National Cancer Advisory Board. She is the first gynecologic oncologist to serve on the Board of Directors for the American Society of Clinical Oncology, the world's largest cancer organization. She also is the author of more than 200 publications, chapters and several books for the public.
Among her many research interests, Dr. Runowicz has largely focused on ovarian, cervical, and breast cancers. She has contributed more than 100 papers to medical literature, including scientific abstracts and textbook chapters. She is widely published in scholarly journals, including the "American Journal of Obstetrics and Gynecology" and the "Journal of Clinical Oncology and Cancer."
As an outspoken advocate for women's health, Dr. Runowicz lectures extensively on issues such as gynecologic cancers, menopause management and breast cancer. She has very candidly shared insights of her own battle with breast cancer, both in speaking appearances and in her book "To Be Alive: A Women's Guide to a Full Life After Cancer," published in 1995.
Co-authored by Dr. Runowicz and her husband Sheldon Cherry, M.D., a New York City gynecologist, "The Menopause Book: A Guide to Women's Health After 40″ was published in 1994. She also co-authored with Jeanne Petrek, M.D., director of the Surgical Program at Memorial Sloan-Kettering Cancer Center, "Women and Cancer: A Thorough and Compassionate Resource for Patients and Their Families" published in 1999. In 2004, Drs. Runowicz and Cherry authored "The Answer to Cancer," offering a comprehensive look at cancer prevention.
Ie-Ming Shih, MD, PhD
Richard TeLinde Distinguished Professor of Gynecologic Pathology
Co-Director, Breast and Ovarian Cancer Program
Dr. Ie-Ming Shih is the Richard TeLinde Distinguished Professor (Endowed Chair) of Gynecologic Pathology and directs this research program at the Johns Hopkins University School of Medicine (1,2). He also co-directs the Breast and Ovarian Cancer Program (3) at the Sidney Kimmel Comprehensive Cancer Center at Hopkins. Dr. Shih received his MD from Taipei Medical University and PhD from the University of Pennsylvania. He is a board-certified pathologist, having completed a clinical fellowship in gynecologic pathology followed by a cancer molecular genetics fellowship at Hopkins. His research focuses on exploring the genomics and pathogenesis of ovarian and endometrial cancer, developing new target-based therapy and applying innovative technology for early detection of gynecologic cancer (2). Dr. Shih's research laboratory has made several discoveries that contribute to our understanding of the pathogenesis of ovarian cancer, including uncovering the genomic landscapes of different histologic subtypes of ovarian cancer, new mechanisms behind chemoresistance, the tumor suppressor roles of ARID1A, and the possible origin of ovarian high-grade serous carcinoma.
Several researchers in the TeLinde Gynecologic Pathology Research Program and Cancer Center have been devoted to identifying and characterizing potential new molecules that can be exploited to target ovarian cancer. The timely and generous gift from the OCRA allows him to build a research team devoted to developing new treatment modalities to improve clinical outcome in ovarian cancer patients. Dr. Shih has published extensively in the field of ovarian cancer research and served on many advisory and editorial boards. In addition to his clinical, research, and teaching obligations, Dr. Shih is also a passionate photographer (4) who wishes to use his talent to help raise fund for ovarian cancer research.
Anil K. Sood, MD
Professor and Vice Chair, Translational Research
Co-Director, Center for RNA Interference and Non-Coding RNA
Director, Blanton-Davis Ovarian Cancer Research Center
Dr. Sood is Professor and Vice Chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology and co-director of the Center for RNA Interference and Non-Coding RNA at the M. D. Anderson Cancer Center.
He is also Director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program. Dr. Sood's research is focused in three main areas: 1) effects of neuroendocrine stress hormones on ovarian cancer growth and progression, 2) development of new strategies for in vivo siRNA delivery, and 3) development of novel anti-vascular therapeutic approaches.
Dr. Sood has received major recognition for his research accomplishments including the Hunter Award, the Margaret Greenfield/Carmel Cohen Excellence in Ovarian Cancer Research Prize, and the GCF/Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher. Dr. Sood is an elected member of the American Society for Clinical Investigation and an elected fellow of the American Association for the Advancement of Science.
Shelley Tworoger, PhD
Associate Center Director of Population Science
Dr. Tworoger is a cancer epidemiologist who joined Moffitt Cancer Center in May, 2017, from Harvard Medical School and Brigham and Women's Hospital. She trained at the University of Washington. The primary goal of her research is to reduce morbidity and mortality from ovarian and breast cancers by enhancing risk prediction models and improving primary and secondary prevention recommendations using an integrative, multidisciplinary approach. Her role as Associate Center Director of Population Science is to advance the scope of population science research across the cancer continuum through leveraging the unique data and consortial resources at Moffitt. Dr. Tworoger was recently appointed as the Principal Investigator of the Moffitt Total Cancer Care initiative; a position she is well suited for as she was the director for the Nurses' Health Studies Biorepositories for over 10 years at Harvard, which included over 3.5 million specimens from more than 200,000 participants.
Emeritus Members:
Jeff Boyd, PhD
Carmel J. Cohen, MD
Bob Ozols, MD, PhD
Michael Seiden, MD, PhD


text:
10-Year T-Notes Fall, Gold Soars, Stocks Slump, Oil Down, But Recession Talk Is Premature
by CD Media Staff August 7, 2019 August 7, 2019 02411
Image: Reinhard Dachlauer
The 10-Year Treasury note fell below 1.7% today, fueling fears of global recession in some corners. Headlines such as "The Dow Is Down…Because Recession Fears Are Growing" from Barron's and are too much, too soon.
Troubling Data? Yes…
The U.S.-China trade war has cast a long shadow over virtually every major financial market. Yes, it is concerning to see treasury yields plumb such depths, and flight to safety makes sense when the top two economies in the world dig their heels in.
Today, stocks fell on lower than expected 10-Year Treasury note yields, though as of 2:00 p.m. EDT, the NASDAQ has just edged back into positive territory. Gold broke through the $1,500 barrier and oil October Brent crude fell 3.2% to $57.04 a barrel, down over 20% since April.
…But Perspective Is Called For
In all of this data, it's easy to lose the signal for all the resulting noise. Apart from Europe's manufacturing weakness, virtually all of the negative market data in recent weeks and months is attributable to the U.S.-China trade conflict turning into a genuine trade war. It's no longer tit-for-tat tariffs and refusals to buy certain goods, now it's formal accusations of currency manipulation that could turn a trade war into a currency war, which could be a globally destabilizing event.
Could be, but won't.
President Trump has an election to win. He will likely push his advantage until it becomes too politically costly, then strike a deal with Beijing. After the election, he can force China back to the table. There are plenty of market makers, economists, and financial writers who suffer from Trump Derangement Syndrome, and their trades, predictions, and words are colored by a fear–and even a perverse hope–that Trump will sink the global economy.
The short-term hope for the U.S. (and the rest of the world who don't want China stealing their technology) is that China's vaunted ability to suffer through hard times has softened due to the spoils of its recent prosperity. It is a virtual impossibility that Xi Jinping and the State Council cave in or even seek to restart talks, but there is the possibility that things are worse behind the communist curtain than falling Chinese stock indexes and weakening export data show.
The bottom line is that any changes on trade are now solely in Trump's hands, and his primary motivation is the economic success of the United States.
China, Not Biden, Is Trump's Biggest Re-Election Hurdle–How To Trade It
China Is Destroying Itself
goldoilstock marketUS Treasury securitiesUS-China trade
AOC In Trouble: Chief Of Staff Resigns, Under Federal Investigation; "Squad" Falling Apart
Bitcoin Price Hits $40,000 Less Than three Weeks After Shattering $20K
China's Top Developer Warns Property Crisis Has "Slid Rapidly Into Severe Depression"
CD Media Staff September 2, 2022 September 2, 2022
BlackRock: Global Economy Could Contract By 11% In The First Half Of 2020
CD Media Staff April 1, 2020 April 1, 2020

redpajama_set_name: RedPajamaCommonCrawl


text:
E.J. Dionne Jr.: Two Taxed Americas
E.J. Dionne Jr. / TruthdigColumnist
WASHINGTON — Ask yourself which politician you trust more.
On the one side, a president who campaigned on a balanced-budget pledge, then dug the country hundreds of billions of dollars deeper into debt with huge tax cuts and an unpaid-for war, and now promises a balanced budget four years after he leaves office.
On the other side, a former senator who says that while he wants to contain the deficit, he has higher priorities than a perfectly balanced budget, specifically universal health insurance coverage and substantial investments in alternative energy.
That is the choice offered by George W. Bush and John Edwards, the North Carolina Democrat whose left-of-center presidential candidacy will have the salutary effect of challenging Barack Obama and Hillary Rodham Clinton to respond with specifics of their own.
Edwards' ideas on the budget have the additional virtue of reminding us that the argument over arriving at a balanced budget by 2012 is largely phony. The real issue, given the burgeoning costs of healthcare and the retirement of the baby boomers, is how to put policies in place now that achieve sustainable fiscal balance — meaning low if not zero deficits — over the next 30 years.
What needs to be done? Hint No. 1: Extending President Bush's tax cuts to eternity would make the long-term problem much worse. Hint No. 2: The hardest part will be how — simultaneously — to meet the fiscal need to rein in health costs and the social need to get health insurance to everyone. Hint No. 3: Most Democrats don't like to talk about it, but taxes are going to have to go up for somebody.
Edwards, at least, is willing to say which taxes he would raise to keep the deficit from going through the roof. He would start by eliminating Bush's tax cuts for the top 2 percent of income earners, which he defines roughly as those earning more than $180,000 to $200,000 a year.
He wants to increase the capital gains tax for an interesting reason: In an interview this week, he argued it's wrong to tax income from work at a higher rate than income from capital — an extension of his longstanding theme that the country should not value "wealth over work." He also favors a windfall-profits tax on oil companies.
But since health coverage and "transforming the energy economy of this country" are first on his to-do list, Edwards says he is prepared to disappoint voters who make a balanced budget their top priority.
Edwards deserves points for honesty and for stating the politically difficult truth that both fiscal and social balance demand a comprehensive healthcare fix.
But his argument doesn't do much to help Democrats on Capitol Hill who have to govern with Bush for the next two years and produce budgets right now that don't worsen the deficit or deepen inequalities. They also need to do something about long-festering social problems. These have been aggravated by declines in health coverage and in the number of families receiving federal help for child care. There is also evidence that many poor people aren't getting the nutrition assistance they need.
Worse: Having watched a Republican president and a Republican Congress run deficits year after year, Democrats will now endure the false piety of born-again Republican deficit hawks who will say they care about a balanced budget more than anything — except, of course, their sacred tax cuts for the wealthy.
"It's a huge mess," Sen. Charles E. Schumer, D-N.Y., said of trying to pass a decent budget. "It's one of the worst things we have to do." Schumer, vice chair of the Democratic Conference, argued that even when Democrats propose increased spending for widely shared goals, such as homeland security, Republicans "are going to say, 'You're spending too much,' even though it's … a mess they created."
Democrats should first do no harm. That means they should resist the temptation of new tax cuts — including repeal of the alternative minimum tax. The AMT should be fixed, but only as part of a comprehensive tax reform that raises revenue. If, as is likely, Bush's path to a "balanced budget" combines tax cuts with freezes or reductions in programs for the needy, Democrats should risk being accused of "class warfare" by pointing out that the president's recipe would produce not fiscal health but further social decline.
And if they want to trump Edwards' candor, Sens. Obama and Clinton should take the lead in showing now how they would begin to clean up the mess they hope to inherit in 2008.
E.J. Dionne Jr.'s e-mail address is postchat(at symbol)aol.com.
Copyright 2007, Washington Post Writers Group
#barack obama#clinton#health care#john edwards
The American People Have Already Lost the 2020 Election
John Feffer / TomDispatch
Bernie Sanders Is Trying to Save the Democratic Party From Itself
Prosecutions of White-Collar Criminals Plunge to All-Time Low
Jake Johnson / Common Dreams
Trump's Afghanistan Deal Has Nothing to Do With Peace
Marjorie Cohn / Truthdig
Happy Afghanistan Surrender Day
Maj. Danny Sjursen / Truthdig
Ralph Nader: Trump Is Becoming a Dictator in Real Time
Ralph Nader / Common Dreams


This case study examines how a documentary, The Double Life of Ernesto Gomez Gomez, can become an instrument for social change, while also giving some important advice on what to focus on when making an issue based film.
From the Making Television Matter book listed above, the outreach campaign for Positive: Life with HIV is detailed, recognizing both the obstacles between independent filmmakers and public television and proposes new ways to overcome them.
From the Making Television Matter book listed above, the outreach campaign for Take the Heart demonstrates the potential for collaboration between funders, filmmakers, television stations, and community organizations.
This comprehensive website contains 12 case studies documenting how producers have integrated educational outreach into their productions. The archived broadcast projects range from children's programs, to one-off documentaries, and to nonfiction limited series. The list includes programs such as Africa, Building Big, Culture Shock, and Cyberchase, among others.
Linking the film with community change is the goal of the outreach campaign surrounding this highly acclaimed documentary from the POV series on PBS. Read this report on the outreach campaign to find out how Two Towns of Jasper is "sparking change one city at a time."
As much an article as a case study, Whiteman examines George Stoney and Judith Helfand's film as an example of a project that raised awareness about lost history.
Go to: Impact of "The Uprising of '34"
Blue Vinyl co-directors Judith Helfand and Daniel Gold "hit the road to tell the truth about America's favorite plastic." After the film, the makers formed partnerships and turned the film into an organizing tool called My House is Your House. Read a report on the results to date of this ground-breaking campaign.


A few digital marketing trends experts expect to see and how PCOs can best take advantage of each.
In order to stay relevant and connected to consumers, a company's digital marketing strategy needs to stay up to date and continually develop to keep pace with competitors. The good news is that in 2019 experts are not expecting any major groundbreaking or revolutionary trends to come out of nowhere and completely change the game. Rather, they anticipate the continual development and increasing importance of trends from the past year to guide brands in the New Year. In particular, video content will become a priority and a social media presence will become a necessity. Pest control companies that are able to evolve their existing digital presence and capitalize on modern trends should succeed in retaining and cultivating loyal customers while also attracting new business.
According to a 2018 survey of businesses across the U.S. by Clutch, 83 percent believe their digital marketing efforts are effective in helping them achieve their goals as a company. However, a 2019 report from Infusionsoft found 29 percent of small business owners surveyed don't plan on utilizing digital marketing this year, citing a lack of time and resources. Although it may seem intimidating, establishing an online presence and executing an effective digital marketing strategy can be done and can deliver exceptional results, even on the smallest of budgets. In 2019, pest control companies without a digital marketing plan will risk being left out of the conversation and ignored by potential consumers who are spending an increasing amount of time online and relying on digital content when making purchasing decisions.
Consumers are increasingly favoring video content when it comes to getting information. In fact, a recent Pew Research Center survey found 73 percent of Americans use the video-sharing platform YouTube, more than any other social media forum (vs. 68 percent of adults who use Facebook).
Whether it's a quick tutorial on how to properly seal cracks or an informational piece regarding a particular pest, video content can be produced on a wide range of budgets and easily distributed across social media platforms, as well as featured on a company website. Videos providing useful information will engage consumers and position your company as an industry expert and go-to resource.
For those who are actively using social media in their digital marketing mix, this one may seem like a no brainer, yet there are still many companies that are not fully on board. It's no secret that social media has become a major aspect of modern-day life, as Statista reports 77 percent of Americans use it. Aside from connecting people with friends and family, platforms allow companies to enter the public dialogue and interact directly with consumers.
In 2019, pest control companies can no longer ignore or underestimate the impact of social media when developing their digital marketing plan. Platforms such as Facebook and Twitter will help companies showcase their capabilities and expertise, while also serving as a valuable customer service tool. According to Ambassador, 71 percent of consumers who have had a good customer service experience with a company via social media are likely to recommend the brand to others.
Is your company using video to better its online footprint? Videos engage consumers and position your company as an industry expert.
Although it may not seem like a "marketing" strategy, monitoring, responding to and encouraging online reviews from customers is essential to a pest control company's digital presence, perception and overall business. Although a Bank of America survey found 51 percent of small business owners don't consider social media reviews and online ratings to be important to their business, BrightLocal determined that 84 percent of people trust online reviews as much as personal recommendations from people they know.
Make sure your company is listed on review sites such as Yelp and optimize your listing by adding company information and photos. Consistently monitor review sites to maintain a sense of public perception, always responding politely and promptly to any negative reviews. Never engage in a public fight or argument with a customer online, no matter how harsh or perhaps unfair the review is. Instead, validate the concern, take the conversation offline and vie for their future business with promises of improved service.
Today, when people search for a pest control company or business they'll likely turn to Google as their first source. Upon doing so, a business' profile will typically appear on the right-hand side of the results, either associated with the company searched or related to the general industry the user is interested in.
Developing and updating your Google "My Business" profile will be essential in 2019, as more and more users are opting to get any needed information from the profile rather than taking a step further and visiting a company's actual website. Be sure to create and/or claim your company's profile, updating it with any relevant information for interested consumers. Do what you can to make it as easy as possible for consumers to find your company and get in contact.
While the increasing participation of people online allows business to potentially connect with more people, this influx of users has also begun to saturate the internet with an almost unmanageable amount of content. Both companies and consumers are producing new materials every day, creating an environment in which digital marketing content that generated buzz just a few years ago now has little to no impact.
There are a number of strategies you can employ to rise above the crowd and reach your customers. First, strive to create content that addresses a subject nobody else has, or rep- ositions a popular subject in a new way. Second, produce content that addresses a difficult subject in a way that's easily under-standable as well as visually appealing. For example, the Professional Pest Management Alliance (PPMA), which serves as the con-sumer education and public outreach arm of the National Pest Management Association (NPMA), recently employed these content principles by videotaping 500,000 termites demolishing a miniature dream home to show-case the dangers of these pests and the need for professional pest management in a unique and eye-catching way.
FINAL THOUGHTS. In 2019, companies won't need to completely revamp their digital marketing strategies or significantly increase their budgets in order to have success. Instead, they'll need to capitalize and adapt to dev- elopments in the digital space, such as the growing impact of social media and increasing popularity of video content. Consumers are spending more and more time online and are putting increasing confidence and weight behind digital content when it comes to making purchasing decisions. By prioritizing smart and effective digital marketing, firms can maximize their time and resources by making worthwhile online impressions, subsequently attracting new customers while building brand loyalty in the year ahead.


Design is the glue that brings together the text and the illustrations.
Some brochures are read. Others are opened, quickly scanned, then filed away. Unfortunately, if a brochure's first impression causes it to be quickly refolded, the odds are that it will never be read. Let's look at a few aspects of effective design.
Color can be used in illustrations, design elements (lines, bars, etc.), the paper, and/or the ink. Using color can have an enormous impact, but remember: Sometimes using just a bit of it is more effective than color everywhere.
Your text is made more readable by the use of short words, short sentences, short paragraphs, and white space.
White space is the unused area in a brochure or booklet. It may seem like a waste if this space is not filled with words, but the opposite is true. Include white space between paragraphs, at the bottom of pages, at the end of sections. Let your text stand out by using lots of white space.


Grace was the eleventh child of Thomas and Elizabeth and was born on the homestead in Washington Co., KS. Her first school was at the Hoffin School. Her opporyunity for school was better than that of her older brothers and sisters and she secured a better education. Alittle instance in her life occured when she was four years old. Her mother, her brother jim,her sister Pearl, and Grace were out at the woodpile when a wagon came driving around the bend. In it were the oldest brother, Tommie, and sister Anna who had both been in the State of Washington for several years and none of the younger children knew them. When they drove into the yard, the mother fainted. Tommie and Anna came running, picked her up, and carried her to the house. The three little children headed for the corn field and it was nearly an hour before they were found there. Grace was a beautiful little redhead and took her turn at housekeeping for the members of the family at home. She was a good and faithful worker, doing her best to please and never complaining. Grace stayed at the home of her sister Ida part of her early life.
Grace and walter began their married life on a farm in Jewell County, Kansas, raising corn and livestock, at which they were quite successful. Later they moved onto a wheat farm near Acres, Kansas. At the time this was compiled, 1 January, 1950, they still had their wheat farming interests near Ashland, Kansas, although they were living in Laverne, Oklahoma.
Grace and Walter had their hardships and heartaches but with their trust in the Lord had found comfort and joy with their four lovely daughters and their grandchildren.


Purchased this RX-8 with a dead engine. After rebuilding it at home, this is my break-in run to help flush out the block.
Car is daily driven 45 miles round trip, mostly highway, so I rack up the miles quick, changing the oil practically every 2 weeks or so.
The capacity is 7 quarts but only 4 drain out during an oil change due to the engine having TWO (2) oil coolers, which hold a bunch of oil along with the oil lines, etc. I do a quick drain n fill, leaving the oil filter on to continue doing it's job. Takes me 5 mins. No big deal.
Not sure how long to run it... these engines are hard on oil and I beat the snot out of it daily. I just want it to last, since these fail due to Lubrication related wear on the Apex Seals. Any recommendations? Haha.
Previous 600 mile runs were on Valvoline 10w40 conventional from Autozone clearance.
Do you run two stroke oil to help lube the combustion chamber? If I had a rotary, that would be something I'd do. With this much oil being left behind, filtration would be also a concern. Also, I'd go through Polaris for analysis to keep tabs on oxidation and things.
Funny, there is a mention of residue. A pure(er) base vs VII loaded one would be cleaner burning, wouldn't it?
The fear of synthetics never made sense to me, this is also widely feared by many motorcycle peeps, " your clutch will [insert assumption]".
Gorgeous car! I've heard that rotaries have greatly improved rotor apex seal life if 2-stroke oil is added to the fuel. I'm not sure what the recommended ratio would be, but I'm sure there's lots of good advice out there.
Many rotary guys add 2 stroke oil to the fuel to lube the apex seals.
I actually use a Rotary specific Pre-Mix Lube added at the recommended 0.5oz per gallon of fuel to help with Apex Seal Lubrication.
I dump 7.5oz with every 13 gallon fill up.
Would love do to a standalone lube injection but those things are expensive. I figured with frequent oil changes + Pre-Lube, the engine should last a good while for me to enjoy my investment / time.
See previous reply about using Rotary specific Pre-Lube that I add to the fuel @ 0.5oz per gallon.
You know, I thought about adding an Amsoil bypass filtration kit, to make sure the oil is super clean and free of particles... haven't pulled the trigger on it yet.
Greg24, do you see how shiny that Mazda is?
Not sure what the big deal would be. There are several guys on the RX-8 forum using Mobil 1 0w40 for a long time. They haven't posted anything negative yet.
As long as it burns clean, I don't think it matters.
I can understand if using a high end synthetic which was designed to resist break down in the Rotary engine that this could cause build up, etc to occur due to the oil not wanting to burn cleanly.
I'm sticking to conventional for now but some Rotary engine builders suggest a synthetic blend. Take the route down the middle they say. haha.
i miss my 06 Shinka, i sold mine with just over 180K on it, ran awesome and lived on supertech 10/40 and TCW3 oil in the fuel. was an amazing car.
Curious, what sort of oil temps does this thing see during spirited driving? With how often you change the oil, nothing wrong with conventional (other than perhaps deposits depending on heat), but I think a lot of the theories about not running synthetic in rotaries has been disproven these days. I used to be into rotaries, and the few guys I still follow on Instagram with built turbo rotaries all run synthetic. Maybe the Renesis is different?
Sizzling oil temps, probably, hence the need for two oil coolers. I haven't installed an oil temp gauge yet. I just closely monitor coolant temps via a Scan Gauge II mounted on the dash.
I'm all pro for synthetic, if I can find one that burns clean. It would obviously offer better protection, so it's a no brainer. Cost would be the only downside for me. The current 10w40 conventional I picked up on clearance costs $2 a quart. It would be hard for me to dump synthetic every few thousand miles @ $8-9 a quart.


Wells Fargo is committed to helping our customers achieve sustainable homeownership. We have long applied responsible lending principles in creating homeownership opportunities. And our commitment extends far beyond the loan closing, as we continue to service customers responsibly — helping them handle the financial aspects of owning a home so they may remain successful homeowners.
Our customers have high expectations for us. They expect respectful, reliable, and knowledgeable service and support — and most importantly, fair and responsible servicing practices. That's why, for many years, we have been guided by our set of Responsible Servicing Principles that support Wells Fargo's vision to satisfy all our customers' financial needs and help them succeed financially.
Wells Fargo services many of the loans we originate, as well as loans that were originated by other lenders and our indirect channels. The majority of these loans are owned by investors who provide guidelines that we must follow when servicing them. On an ongoing basis, we collaborate with our investors to introduce helpful options for our customers, while remaining in compliance with set requirements.
We proactively help our customers manage, protect, and keep their homes. As a result, our delinquency and foreclosure rates continue to be below the industry average. Behind our efforts is the understanding that our customers, communities, and all parties involved in the process benefit when homeownership is preserved.
Four core principles serve as a guide for our practices and our team members. These principles for servicing our customers are simple and straightforward — serving as the compass that guides us every day.
Principle #1: Provide clear, simple, timely information and tools to help customers understand homeownership and financing.
Making it easy and convenient for customers to access and use a vast array of resources, references and helpful information, including clear, detailed mortgage statements, and our comprehensive website.
Ensuring customers have knowledgeable service representatives standing by to answer questions, resolve issues, and make it comfortable for customers to contact us, especially if they experience financial challenges.
Providing tools and educational programs — at Wells Fargo and through local organizations and credit counselors — that help customers better understand money management, their credit reports, and the importance of maintaining good credit.
Principle #2: Deliver what we believe our customers deserve - a dedicated and knowledgeable service team - by hiring and retaining experienced professionals who excel in serving customers.
Training our team members extensively, monitoring performance, and routinely providing feedback to ensure they are doing the best job they can for customers.
Assigning a single point of contact to each customer who experiences financial challenges and needs to explore mortgage assistance options. This home preservation specialist will remain dedicated to working with the customer throughout the mortgage assistance process.
Principle #3: Build a bridge to our customers based on respect and attention to individual needs.
Taking the extra effort needed to understand each customer, so we may provide the help he or she needs.
Promptly researching and resolving complaints.
Making it a practice to do what is right for the customer.
Continuously striving to improve our processes.
Principle #4: Do all we can to keep people in their homes — because we believe in homeownership.
Our commitment to contacting customers who need assistance, and actively working with them to avoid delinquency.
After determining a customer is unable to make payments, we begin working with the customer to explore options and potential solutions.
Recognizing that all customers have unique financial situations and reviewing available options on an individual case-by-case basis.
Viewing foreclosure as a last resort.
Provide clear, simple, timely information and tools to help customers understand homeownership and financing.
Deliver what we believe our customers deserve — a dedicated and knowledgeable service team — by hiring and retaining experienced professionals who excel in serving customers.
Build a bridge to our customers based on respect and attention to individual needs.
Do all we can to keep people in their homes — because we believe in homeownership.
Wells Fargo remains committed to living by responsible lending and servicing principles, encouraging responsible and respectful treatment of customers. We're here for our customers, in good times and bad. And we continue to work closely with other members in the housing finance industry, seeking ways to expand and preserve homeownership — making it achievable and sustainable.


text:
Q: Backbone model change event not firing after setting model I took an non kosher approach and used the $.ajax() for an ajax file upload because at the moment I can't figure out the "backbone" way. The picture has been uploaded and the ajax request sends back the new backbone model in JSON, populated with the filename of the new photo. However the model is not firing a change event so I can't populate the profile picture. See the success function below.
    getFile:function(e){
        e.preventDefault();
        that = this;
        var file = e.target.files[0];
        name = file.name;
        size = file.size;
        type = file.type;
        var formData = new FormData($('#upload-child-pic-form')[0]);
        console.log(this,'currentUploadU',this.currentUpload);
        formData.append('child_id',this.currentUpload);
        $.ajax({
            url: '/children/upload/',
            type: 'POST',
            xhr: function() {
            var myXhr = $.ajaxSettings.xhr();
                if(myXhr.upload){
                    myXhr.upload.addEventListener('progress',function(data){
                        $("#upload-child-pic-progress").val(data.position / data.totalSize * 100);
                    }, false);
                }
                return myXhr;
            },
            //Ajax events
            beforeSend: function(data){
                $("#upload-child-pic-progress").removeClass('hide');
            },
            success: function(data){
                $("#upload-child-pic-progress").addClass('hide');
                $("#add-child-profile-pics-modal").modal('hide');
                var sentData = $.parseJSON(data);
                var thisChild = that.children.get(sentData.id);
                thisChild.set("photo",sentData.photo);
                thisChild.trigger('change');
            },
            error: function(data){
                console.log('error',data);
            },
            // Form data
            data: formData,
            //Options to tell jQuery not to process data or worry about content-type.
            cache: false,
            contentType: false,
            processData: false
        });
    },

A: You are missing var before the that variables and other variables...
having these variable global is a menace, they can be changed/overwritten outside of this scope before the success callback is called.
that = this; //should be - 'var that = this;'

redpajama_set_name: RedPajamaStackExchange


text:
Linda Santmyer
December 21, 1950,- January 20, 2021 Linda Santmyer 71, passed away in Casa Grande, born in Welch, WV., lived in Fredriclesburg VA for most of her life. She retired to live in Casa Grande 4 years ago. She was married for 51 years., to Elmer Santmyer. She is survived by her children: Sandy, Stefan, of Hopwood, Pa., Bobby Santmyer of Harrisonburg, VA., James Santmyer of Ruthe Glen, VA. Sister: Carolyn Allen of Hurt, VA. brother: Clyde Cox of Mesa, Az and 9 grandchildren. She
Ron Lee Burton
September 1939- January 18, 2021 Ron Burton, 81 of Casa Grande Arizona, passed away peacefully. Of Covid Pneumonia at Casa Grande Reginal Hospital after a loving visit with his daughter and wife. Born in Plattsburg, Missouri to Rose &Melvin Burton. Ron was the youngest of 5 siblings, he lost his parents at a young age and he was raised by his loving aunts Helen Howard and Carrie Musser. In 1958, he enlisted in the U.S. Army and served for 3 years as a Marksman during the Vi
Manuel Rodriguez,63, of Eloy died on Jan.15,2021, in Casa Grande. Mr. Rodriguez was born on July 14, 1957. He was a man who was loved dearly by his family. He was always smiling and had good conversations with everyone while ensuring the share to share the love of God. He dedicated himself to take the word of God to people's hearts. With his wife by his side for 20 years, they made many delicious tamales. Survivors include his wife, Nohemi F.: five adult children: Elias, Tosu
Michael Ralston
Michal Ralston, 60, of Casa Grande died on January 19, 2021. Mr. Ralston was born on December. 13, 1960. He was a heavy equipment operator, pipefitter, and welder. His hobbies included bowling, shooting pool for fun, and playing bingo. He loved his cats and they loved him. He is survived by his mother and stepfather, LaNeva and Thomas Jenkins, and a sister, Lynette Vanderlip. He was preceded in death by his father, Mikey Ralston. Memorial service at a later date. Memorial con
James Bloam
James Bloam, 66 born March 30th, 1954 in Cleveland Ohio, and passed away on Jan., 16th at home under the care of hospice and his family after a valiant battle with Non-Hodgkins' lymphoma. In 1979 Jim became a firefighter paramedic for the Cuyahoga Heights Fire Department where he served for 31 years. In 1987 as MDA coordinator, he started the MDA fifties dance and car show. The annual event raises hundreds of thousands of dollars for MDA. Jim retired to Arizona with his wife
Juan A Villegas Valdez
Aug. 22, 1941- Jan 17, 2021 Juan A Villegas Valdez passed away at home at the age of 79 in Casa Grande. He was an ordained minister of his church and enjoyed serving the members. He loved his cactus garden and all his trees, any outdoor activity. Most of all he enjoyed the family gatherings throughout the year. Juan survived by his wife Consuelo M. Villegas. Children: Juan M. Montenegro, Francisco J. Villegas, Juan A Villegas. Maria J. Ortega, Joel Villegas, Noel Villegas, M
Candy Maria Sanchez
Sep. 12,1949- Jan. 21, 2021 Maria Sanchez 71, passed away in Casa Grande. she worked for Little Sombrero and a teacher at Sunday school. She loved to bake, cook, and sewing, but especially she loved spending time with her husband and grandchildren. She always her home to anyone in need, She liked to read her Bible, word search, and coloring. Maria was a beautiful person. She is survived by her husband Raul H. Sanchez of 40 years, daughters: Veronica Hernandez, of Casa Grand
Susan Brakefield
October- 5, 1984 -January, 19-2021 Susan Brakefield, born in Casa Grande, passed away at 37. She grew up outside Oklahoma City. She spent her final years in Casa Grande. She was a very talented artist and singer. Loved her Dr. Pepper and anime, unicorns, and Asian artwork. She will be missed by her family at Somerset Manor. Surviving family, brothers: Mike Mckee, Tom Ethington, two nephews: Ian and Graham, and her beloved dog Remy Services at Sunset Mannor 1, 29, from
Felipe P. Ibarra
Oct. 30, 1948- Jan 26, 2021 Felipe P. Ibarra passed away at 72, in Eloy, Az. He was born October 30, 1948, to Eliu S. and Elodia P. Ibarra in Elsa Texas. They moved to Arizona in Feb. 1961 when he was 13 years old. He worked out on the farms to help his father. He married Helen Villarreal in 1968 and was with her until 1987. They had 4 children: Elizabeth, Felipe Jr., Eliu Leandro, and Jonatan Andrew Ibarra. In 1988 he married Martina Pesina and was married to her for 33 year
Dominick Magliaro
November 22, 1941 - December 22, 2020 Dominick was taken by the Lord on December 22, 2020, after a long battle with cancer. He was surrounded by his loving family. Dominick was born to Rose and Carl Magliaro on November 22, 1941, in New York City. He loved bowling and was an award-winning champion. He also enjoyed playing cards with his buddies every Friday night on the farm. He moved his family from the east coast to Casa Grande forty -four years ago to be Advertising Direct
Nancy Ellen Smith
Jeffery Bryan Barnett-Marciano
Vanette Frances Martin
Edward C. Castro
Andrea Nicole Tapia
Barbara Ellen Wilden
Gordan Beck Jr.
Mario Ybarra, Sr.
Jason R. Moe
Doreen Eleanor Leggitt


text:
Cañon City Area Recreation and Park District…
Cañon City Area Recreation and Park District Executive Director Jim Hoar to retire in June
Carie Canterbury/ Daily Record
Don Tuff, contractor desk supervisor at Home Depot, left, and Jim Hoar, executive director of the Cañon City Area Metropolitan Recreation and Park District, stand next to a sign introducing the new Arkansas Riverwalk Fitness Course in 2016. Hoar will retire as executive director of the district in June.
PUBLISHED: March 15, 2018 at 6:41 am | UPDATED: April 15, 2019 at 4:01 am
The Cañon City Area Recreation and Park District board accepted a letter of retirement Tuesday from Executive Director Jim Hoar, who has served as director for 17 years.
According to a press release, Hoar's final day will be June 30. The board will start the selection process now to transition to a new director.
"Jim will certainly be missed. His leadership has advanced the district in a multitude of ways," Board President Ken Burger said in the press release. "He is one of the hardest working individuals that I have ever had the pleasure of knowing. The things that were accomplished by the district during his tenure are simply remarkable. I personally appreciate everything that Jim has done for the district during my eight years as a board member."
Under Hoar's leadership, the district has expanded both in size and in the number of facilities, amenities, trails and open space acreage it manages.
In 2002, the geographical area the district services increased to 115 square miles in size with a successful inclusion election. The land that would become home to Pathfinder Regional Park was purchased in 2006 with the grand opening of the park in 2007. A fishing pond was added in 2008 and the Miner's Pavilion in 2012.
More recently, in 2016, Hoar facilitated the donation of a 160-acre parcel of land from Walter Schepp and the purchase of the Summit Brick property. These have been developed into the Eagle Wing Trailhead, South Canon Trail system and Schepp Open Space.
In his first year as director, the property at 575 Ash St. was acquired through a lease-purchase agreement to house the district's offices. Through the years, the facilities on the property have grown to include the Arkansas Riverwalk Dog Park in 2011, the Ash Street Community Garden in 2013, the renovation of the archery range in 2014 and construction of an elevated shooting stand in 2015.
Notable enhancements to the parks and trails under the district's management also occurred during Hoar's tenure. The district acquired the old Harrison School playground in 2008 and the redeveloped park opened in 2012. To the west, the Arkansas Riverwalk Trail was extended to Ninth Street in 2004. The trail was extended to the east to the Mackenzie Avenue Trailhead in 2012.
"I am extremely proud of what we have accomplished under the leadership of this board and those board members before them," Hoar said in the press release. "I have always believed that I was just one part of a much larger team of dedicated public service employees and volunteers. I thank the community for the opportunities we have been given and all the fine people I have had the privilege to work with and work for. Together, we have made a wonderful difference in the quality of life in our community."


I decided to start with Vision Personal Training Bundall and do a fitness programme as I was overweight and just felt unhealthy. I needed to get some control back into my life.
I chose Vision because I had been to them a couple of years before and got fantastic results, 30kg loss in 12 months. I needed Visions support, encouragement and accountability for my exercise and eating plan. I like how they offer one on one with a Trainer and to know that I could join in the goups sessions as well.
My journey so far has been slow, but I love the encouragement and support not only from the team at Vision but also the other Visionaries. It's fun and I can have a laugh even though its hard work.
Vision has changed my life as I'm more confident and pain free. For me, this is a lifestyle change. I've tried to do it on my own but I need the accountability. I will be with Vision forever as I have made some really good friends. Once my goal weight is achieved, I will be looking for other fitness challenges within Vision.
I would thoroughly recommned Vision to anyone as everyone has different needs/expectations and Vision will help you reach your goals. I've found all the Trainers to be highly experienced and professional in everything they do.